Description

Product Description

Elpamotide (CAS 673478-49-4) is a therapeutic peptide derived from vascular endothelial growth factor receptor 2 (VEGFR2). As a tumor vasculature-targeting vaccine candidate, Elpamotide plays a significant role in the development of cancer immunotherapy strategies.

Background on VEGFR2 and Tumor Angiogenesis

• VEGFR2 is a major receptor involved in tumor angiogenesis, regulating endothelial cell survival, proliferation, and new blood vessel formation.

• Overexpression of VEGFR2 is associated with the growth and metastasis of various cancers, including pancreatic cancer, colorectal cancer, and hepatocellular carcinoma.

• Targeting VEGFR2-expressing endothelial cells provides a novel strategy to inhibit tumor angiogenesis.

Research Role of Elpamotide

1. Cancer Immunotherapy

   • Elpamotide stimulates CTLs to specifically recognize and destroy VEGFR2-expressing endothelial cells.

   • Reduces tumor vascularization and suppresses tumor progression.

2. Antineoplastic Effects

   • Demonstrates immunostimulatory activity by enhancing immune recognition of tumor vasculature.

   • Potential use in multiple cancers, with strong evidence in pancreatic cancer models.

3. Epitope-Specific CTL Induction

   • Elpamotide mimics VEGFR2-derived epitopes, training the immune system to mount a specific adaptive immune response.

   • Provides selective killing of tumor blood vessel endothelium without broadly damaging normal tissues.

4. Vaccine Development

   • Functions as a peptide-based vaccine candidate.

   • May synergize with other cancer treatments, such as chemotherapy, checkpoint inhibitors, or angiogenesis inhibitors.

Product Specifications

Mechanism of Action

Elpamotide exerts its effects by stimulating an adaptive immune response against tumor vasculature.

1. Epitope Presentation

   • Elpamotide, a VEGFR2-derived peptide, is processed and presented on MHC class I molecules of antigen-presenting cells (APCs).

2. CTL Induction

   • Activates cytotoxic T lymphocytes, which specifically recognize VEGFR2-derived epitopes.

3. Targeted Killing of Endothelial Cells

   • CTLs selectively kill VEGFR2-positive endothelial cells within tumor blood vessels.

   • Disruption of tumor vasculature deprives tumors of nutrients and oxygen.

4. Immunostimulatory Cascade

   • Promotes immune memory formation, enabling long-term tumor control.

   • Enhances infiltration of immune cells into the tumor microenvironment.

5. Synergistic Antitumor Effects

   • Can be combined with chemotherapy or immune checkpoint inhibitors to enhance efficacy.

   • Works as part of multi-modality cancer therapy approaches.

     

Side Effects

Observed in Research

• Induces targeted immune responses without widespread damage to normal tissues.

• Some inflammatory responses observed, consistent with immune activation.

Potential Risks

• May cause vascular inflammation in VEGFR2-expressing normal tissues.

• Risk of autoimmune responses with repeated dosing.

• Dependent on immune system status of the host organism.

Laboratory Safety Notes

• For research use only.

• Handle under sterile peptide-handling protocols.

• Store at appropriate conditions to maintain peptide integrity.

Disclaimer

Elpamotide is supplied strictly for laboratory research purposes only. It is not approved for diagnostic or therapeutic use in humans.

Keywords

Elpamotide, CAS 673478-49-4, VEGFR2 peptide, epitope peptide, CTL inducer, tumor immunotherapy peptide, antiangiogenic peptide, pancreatic cancer research, cancer vaccine candidate.

Shipping Guarantee

We provide reliable worldwide shipping services:

• Customs-cleared & tax-inclusive deliveries.

• 100% full compensation for any product loss or damage during transit.

• Secure, trackable, and efficient logistics.

Transaction Guarantee

We support multiple safe and flexible payment methods:

• T/T bank transfer

• PayPal

• Cryptocurrencies (BTC, ETH, USDT, etc.)

• Other payment methods available upon request

We guarantee secure, transparent, and convenient transactions for all research products.